Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry.
anaphylaxis
drug hypersensitivity
drugs
multicenter study
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
11
10
2022
received:
21
03
2022
accepted:
01
11
2022
medline:
2
6
2023
pubmed:
9
12
2022
entrez:
8
12
2022
Statut:
ppublish
Résumé
Drugs are a frequent cause of severe anaphylactic reactions. Here, we analyze a large dataset on drug induced anaphylaxis regarding elicitors, risk factors, symptoms, and treatment. Data from the European Anaphylaxis Registry (2007-2019) with 1815 reported cases of drug-induced anaphylaxis were studied accordingly. Drugs are the third most frequent cause of anaphylaxis reported in the Anaphylaxis Registry. Among the eliciting groups of drugs analgesics and antibiotics were far most often reported. Female and senior patients were more frequently affected, while the number of children with DIA was low. DIA patients had symptoms affecting the skin and mucous membranes (n = 1525, 84.02%), the respiratory (n = 1300, 71.63%), the cardiovascular (n = 1251, 68.93%) and the gastrointestinal system (n = 549, 30.25%). Drugs caused significant more severe reactions, occurred more often in medical facilities and led to increased hospitalization rates in comparison to food and insect venom induced anaphylaxis. Adrenaline was used more often in patients with DIA than in anaphylaxis due to other causes. Patients with skin symptoms received more antihistamines and corticosteroids in the acute treatment, while gastrointestinal symptoms led to less adrenaline use. The study contributes to a better understanding of DIA, with a large number of cases from Europe supporting previous data, e.g., analgesics and antibiotics being the most frequent culprits for DIA. Female gender and higher age are relevant risk factors and despite clear recommendations, the emergency treatment of DIA is not administered according to the guidelines.
Sections du résumé
BACKGROUND
Drugs are a frequent cause of severe anaphylactic reactions. Here, we analyze a large dataset on drug induced anaphylaxis regarding elicitors, risk factors, symptoms, and treatment.
METHODS
Data from the European Anaphylaxis Registry (2007-2019) with 1815 reported cases of drug-induced anaphylaxis were studied accordingly.
RESULTS
Drugs are the third most frequent cause of anaphylaxis reported in the Anaphylaxis Registry. Among the eliciting groups of drugs analgesics and antibiotics were far most often reported. Female and senior patients were more frequently affected, while the number of children with DIA was low. DIA patients had symptoms affecting the skin and mucous membranes (n = 1525, 84.02%), the respiratory (n = 1300, 71.63%), the cardiovascular (n = 1251, 68.93%) and the gastrointestinal system (n = 549, 30.25%). Drugs caused significant more severe reactions, occurred more often in medical facilities and led to increased hospitalization rates in comparison to food and insect venom induced anaphylaxis. Adrenaline was used more often in patients with DIA than in anaphylaxis due to other causes. Patients with skin symptoms received more antihistamines and corticosteroids in the acute treatment, while gastrointestinal symptoms led to less adrenaline use.
CONCLUSION
The study contributes to a better understanding of DIA, with a large number of cases from Europe supporting previous data, e.g., analgesics and antibiotics being the most frequent culprits for DIA. Female gender and higher age are relevant risk factors and despite clear recommendations, the emergency treatment of DIA is not administered according to the guidelines.
Substances chimiques
Epinephrine
YKH834O4BH
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1615-1627Informations de copyright
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472
Worm M, Eckermann O, Dölle S, et al. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int. 2014;111(21):367-375. doi:10.3238/arztebl.2014.0367
OECD. Health at a Glance 2019: OECD Indicators. OECD Publishing; 2019, Health at a Glance 2019: OECD Indicators. Accessed June 19, 2020, page 209.
Panesar SS, Javad S, de Silva D, et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy. 2013;68(11):1353-1361. doi:10.1111/all.12272
Kidon M, Blanca-Lopez N, Gomes E, et al. EAACI/ENDA position paper: diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29(5):469-480. doi:10.1111/pai.12915
Chaaban MR, Warren Z, Baillargeon JG, Baillargeon G, Resto V, Kuo YF. Epidemiology and trends of anaphylaxis in the United States, 2004-2016. Int Forum Allergy Rhinol. 2019;9(6):607-614. doi:10.1002/alr.22293
Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. Thorax. 2007;62(1):91-96. doi:10.1136/thx.2004.038844
Lieberman PL. Recognition and first-line treatment of anaphylaxis. Am J Med. 2014;127(1 Suppl):S6-S11. doi:10.1016/j.amjmed.2013.09.008
Turner PJ, Campbell DE, Motosue MS, Campbell RL. Global trends in anaphylaxis epidemiology and clinical implications. J Allergy Clin Immunol Pract. 2020;8(4):1169-1176. doi:10.1016/j.jaip.2019.11.027
Bilò MB, Corsi A, Martini M, Penza E, Grippo F, Bignardi D. Fatal anaphylaxis in Italy: analysis of cause-of-death national data, 2004-2016. Allergy. 2020;75(10):2644-2652. doi:10.1111/all.14352
Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135(4):956-963.e1. doi:10.1016/j.jaci.2014.10.021
Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol. 2017;140(2):321-333. doi:10.1016/j.jaci.2017.06.012
R Core Team. (2021). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
Whocc.no. 2021. WHOCC - ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
Wood RA, Camargo CA Jr, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461-467. doi:10.1016/j.jaci.2013.08.016
Aurich S, Dölle-Bierke S, Francuzik W, et al. Anaphylaxis in elderly patients-data from the European anaphylaxis registry. Front Immunol. 2019;10:750. Published 2019 Apr 24. doi:10.3389/fimmu.2019.00750
Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011;71(5):684-700. doi:10.1111/j.1365-2125.2010.03774.x
Francuzik W, Kraft M, Scherer Hofmeier K, et al. Anaphylaxis in middle-aged patients. Allergol Select. 2021;5:133-139. Published 2021 Mar 23. doi:10.5414/ALX02216E
Francuzik W, Ruëff F, Bauer A, et al. Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European anaphylaxis registry. J Allergy Clin Immunol. 2021;147(2):653-662.e9. doi:10.1016/j.jaci.2020.06.008
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(6):1318-1328.e7. doi:10.1016/j.jaci.2014.08.018
Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, asthma and Immunology epidemiology of anaphylaxis working group. Ann Allergy Asthma Immunol. 2006;97(5):596-602. doi:10.1016/S1081-1206(10)61086-1
van der Klauw MM, Wilson JH, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974-1994) and review of the literature. Clin Exp Allergy. 1996;26(12):1355-1363. doi:10.1046/j.1365-2222.1996.d01-300.x
Faria E, Rodrigues-Cernadas J, Gaspar A, et al. Drug-induced anaphylaxis survey in Portuguese allergy departments. J Investig Allergol Clin Immunol. 2014;24(1):40-48.
Orhan F, Canitez Y, Bakirtas A, et al. Anaphylaxis in Turkish children: a multi-Centre, retrospective, case study. Clin Exp Allergy. 2011;41(12):1767-1776. doi:10.1111/j.1365-2222.2011.03859.x
Ye YM, Kim MK, Kang HR, et al. Predictors of the severity and serious outcomes of anaphylaxis in korean adults: a multicenter retrospective case study. Allergy Asthma Immunol Res. 2015;7(1):22-29. doi:10.4168/aair.2015.7.1.22
Hox V, Desai A, Bandara G, Gilfillan AM, Metcalfe DD, Olivera A. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol. 2015;135(3):729-736.e5. doi:10.1016/j.jaci.2014.11.003
Francuzik W, Nassiri M, Babina M, Worm M. Impact of sex on anaphylaxis severity-data from the Anaphylaxis Registry. J Allergy Clin Immunol. 2015;136(5):1425-1426. doi:10.1016/j.jaci.2015.06.052
World Health Organization. The World Health Report 2019: Primary Health Care - Now more than Ever. World Health Organization; 2019.
Poowuttikul P, Seth D. Anaphylaxis in children and adolescents. Pediatr Clin North Am. 2019;66(5):995-1005. doi:10.1016/j.pcl.2019.06.005
Ribeiro-Vaz I, Marques J, Demoly P, Polónia J, Gomes ER. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese pharmacovigilance authority. Eur J Clin Pharmacol. 2013;69(3):673-681. doi:10.1007/s00228-012-1376-5
Atanaskovic-Markovic M, Gomes E, Cernadas JR, et al. Diagnosis and management of drug-induced anaphylaxis in children: an EAACI position paper. Pediatr Allergy Immunol. 2019;30(3):269-276. doi:10.1111/pai.13034
Kim SY, Kim MH, Cho YJ. Different clinical features of anaphylaxis according to cause and risk factors for severe reactions. Allergol Int. 2018;67(1):96-102. doi:10.1016/j.alit.2017.05.005
Worm M, Francuzik W, Renaudin JM, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from the European anaphylaxis registry. Allergy. 2018;73(6):1322-1330. doi:10.1111/all.13380
Renaudin JM, Beaudouin E, Ponvert C, Demoly P, Moneret-Vautrin DA. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the allergy vigilance network from 2002 to 2010. Allergy. 2013;68(7):929-937. doi:10.1111/all.12168
Grabenhenrich LB, Dölle S, Ruëff F, et al. Epinephrine in severe allergic reactions: the European anaphylaxis register. J Allergy Clin Immunol Pract. 2018;6(6):1898-1906.e1. doi:10.1016/j.jaip.2018.02.026
Sicherer SH, Simons FER, Section on Allergy and Immunology. Epinephrine for first-aid management of anaphylaxis. Pediatrics. 2017;139(3):e20164006. doi:10.1542/peds.2016-4006
Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77(2):357-377. doi:10.1111/all.15032
Beyer K, Eckermann O, Hompes S, Grabenhenrich L, Worm M. Anaphylaxis in an emergency setting - elicitors, therapy and incidence of severe allergic reactions. Allergy. 2012;67(11):1451-1456. doi:10.1111/all.12012
Gaspar A, Santos N, Faria E, et al. Anaphylaxis: a decade of a Nationwide allergy society registry. J Investig Allergol Clin Immunol. 2021;32(1):23-32. doi:10.18176/jiaci.0515
Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol. 2001;108(5):861-866. doi:10.1067/mai.2001.119028
Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123(2):434-442. doi:10.1016/j.jaci.2008.10.049
Doña I, Blanca-López N, Torres MJ, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22(5):363-371.
Montañez MI, Mayorga C, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614. Published 2017 May 29. doi:10.3389/fimmu.2017.00614
Mota I, Gaspar Â, Benito-Garcia F, Correia M, Chambel M, Morais-Almeida M. Drug-induced anaphylaxis: seven-year single-center survey. Eur Ann Allergy Clin Immunol. 2018;50(5):211-216. doi:10.23822/EurAnnACI.1764-1489.66
Blanca-Lopez N, Soriano V, Garcia-Martin E, Canto G, Blanca M. NSAID-induced reactions: classification, prevalence, impact, and management strategies. J Asthma Allergy. 2019;12:217-233. Published 2019 Aug 8. doi:10.2147/JAA.S164806
Aun MV, Blanca M, Garro LS, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol Pract. 2014;2(4):414-420. doi:10.1016/j.jaip.2014.03.014
Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28-39. doi:10.1111/all.13599
Cochran ST. Anaphylactoid reactions to radiocontrast media. Curr Allergy Asthma Rep. 2005;5(1):28-31. doi:10.1007/s11882-005-0051-7
Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9
Trautmann A, Goebeler M, Stoevesandt J. Twenty Years' experience with anaphylaxis-like reactions to local anesthetics: genuine allergy is rare. J Allergy Clin Immunol Pract. 2018;6(6):2051-2058.e1. doi:10.1016/j.jaip.2018.04.005